Physiologic and metabolic influences on enterohepatic recirculation: simulations based upon the disposition of valproic acid in the rat
- PMID: 2013839
- DOI: 10.1007/BF01073869
Physiologic and metabolic influences on enterohepatic recirculation: simulations based upon the disposition of valproic acid in the rat
Abstract
The potential influence of alterations in several physiologic processes (hepatocellular egress, biliary excretion, gastrointestinal transit) and biotransformation steps (oxidative metabolism, glucuronidation) on the disposition of agents subject to significant enterohepatic recirculation (ER) via the glucuronide conjugate was examined in a series of simulation experiments. The model of ER developed was based upon the disposition of valproic acid (VPA) and valproate glucuronide (VPA-G) in the rat. The systemic disposition of VPA was simulated following changes in several processes contributing to (or competing with) ER: hepatic oxidative metabolism, hepatic glucuronidation, sinusoidal egress of glucuronide conjugate, canalicular egress of glucuronide conjugate, and gastrointestinal transit. Changes in the formation clearance of VPA-G resulted in a less than proportional change in systemic clearance of VPA, whereas changes in oxidative metabolism led to a greater than proportional change in systemic clearance. Furthermore, alterations in hepatocellular egress of VPA-G affected the disposition of the parent compound, suggesting that drug interactions or disease state effects on metabolite transport may be misinterpreted as effects at the level of metabolite formation. Analytical methods are proposed to recover the intrinsic kinetic parameters (formation clearances of metabolites, renal clearance of parent, volume of distribution) in the presence of ER from the systemic disposition of the parent alone.
Similar articles
-
Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions.Hepatology. 1996 Apr;23(4):771-80. doi: 10.1002/hep.510230418. Hepatology. 1996. PMID: 8666331
-
Probenecid-associated alterations in valproate glucuronide hepatobiliary disposition: mechanistic assessment using mathematical modeling.J Pharmacol Exp Ther. 2001 Apr;297(1):141-7. J Pharmacol Exp Ther. 2001. PMID: 11259538
-
Panipenem, a carbapenem antibiotic, enhances the glucuronidation of intravenously administered valproic acid in rats.Drug Metab Dispos. 1999 Jun;27(6):724-30. Drug Metab Dispos. 1999. PMID: 10348803
-
Probenecid-associated alterations in valproic acid pharmacokinetics in rats: can in vivo disposition of valproate glucuronide be predicted from in vitro formation data?Drug Metab Dispos. 2000 Dec;28(12):1433-9. Drug Metab Dispos. 2000. PMID: 11095580
-
Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.Clin Pharmacokinet. 2002;41(10):751-90. doi: 10.2165/00003088-200241100-00005. Clin Pharmacokinet. 2002. PMID: 12162761 Review.
Cited by
-
Sex related differences on valproic acid pharmacokinetics after oral single dose.J Pharmacokinet Pharmacodyn. 2013 Aug;40(4):479-86. doi: 10.1007/s10928-013-9323-3. Epub 2013 Jun 20. J Pharmacokinet Pharmacodyn. 2013. PMID: 23784346 Clinical Trial.
-
Enteric reabsorption processes and their impact on drug pharmacokinetics.Sci Rep. 2021 Mar 11;11(1):5794. doi: 10.1038/s41598-021-85174-w. Sci Rep. 2021. PMID: 33707635 Free PMC article.
-
Age-dependent intestinal absorption of valproic acid in the rat.Pharm Res. 1995 Feb;12(2):284-90. doi: 10.1023/a:1016295329865. Pharm Res. 1995. PMID: 7784346
-
Possible mechanism by which the carbapenem antibiotic panipenem decreases the concentration of valproic acid in plasma in rats.Antimicrob Agents Chemother. 1998 Dec;42(12):3136-40. doi: 10.1128/AAC.42.12.3136. Antimicrob Agents Chemother. 1998. PMID: 9835504 Free PMC article.
-
A Continuous Intestinal Absorption Model to Predict Drug Enterohepatic Recirculation in Healthy Humans: Nalbuphine as a Model Substrate.Mol Pharm. 2024 Sep 2;21(9):4510-4523. doi: 10.1021/acs.molpharmaceut.4c00424. Epub 2024 Jul 2. Mol Pharm. 2024. PMID: 38956965